New approaches in the treatment of MDS: an overview of current trials.
Jehn
U
U
Medizinische Klinik III, Ludwig-Maximilians Universität München, FRG.
D000368:Aged; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D001772:Blood Cell Count / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D003561:Cytarabine / Q000627:therapeutic use; D000077209:Decitabine; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy*
D016298:Hematopoietic Cell Growth Factors; D003561:Cytarabine; D000077209:Decitabine; D015474:Isotretinoin; D001374:Azacitidine